Alkem Laboratories Limited

NSEI:ALKEM Stock Report

Market Cap: ₹628.4b

Alkem Laboratories Future Growth

Future criteria checks 1/6

Alkem Laboratories is forecast to grow earnings and revenue by 10.7% and 9.5% per annum respectively. EPS is expected to grow by 10.6% per annum. Return on equity is forecast to be 18.6% in 3 years.

Key information

10.7%

Earnings growth rate

10.6%

EPS growth rate

Pharmaceuticals earnings growth17.6%
Revenue growth rate9.5%
Future return on equity18.6%
Analyst coverage

Good

Last updated20 Jan 2025

Recent future growth updates

Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Nov 16
Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 13
Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Jun 01
Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Feb 13
Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Recent updates

Alkem Laboratories Limited's (NSE:ALKEM) Shares May Have Run Too Fast Too Soon

Feb 01
Alkem Laboratories Limited's (NSE:ALKEM) Shares May Have Run Too Fast Too Soon

Is Alkem Laboratories (NSE:ALKEM) A Risky Investment?

Jan 10
Is Alkem Laboratories (NSE:ALKEM) A Risky Investment?

Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Nov 16
Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching

Nov 15
Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching

What Alkem Laboratories Limited's (NSE:ALKEM) P/E Is Not Telling You

Sep 24
What Alkem Laboratories Limited's (NSE:ALKEM) P/E Is Not Telling You

Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?

Sep 03
Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?

Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 13
Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 27
Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00

Jul 13
Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Jun 27
Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00

Jun 13
Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00

Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Jun 01
Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)

May 22
Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Feb 13
Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Earnings and Revenue Growth Forecasts

NSEI:ALKEM - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2027161,54927,52819,79023,26918
3/31/2026147,43125,36116,92121,12420
3/31/2025133,32522,34215,90623,79420
9/30/2024128,31921,22315,05419,549N/A
6/30/2024127,31720,542N/AN/AN/A
3/31/2024126,67617,95816,88819,481N/A
12/31/2023126,34415,732N/AN/AN/A
9/30/2023123,51414,32918,37020,537N/A
6/30/2023119,90611,433N/AN/AN/A
3/31/2023115,9939,84214,49616,825N/A
12/31/2022111,80510,208N/AN/AN/A
9/30/2022107,58610,9175,5278,426N/A
6/30/2022104,79213,051N/AN/AN/A
3/31/2022106,34216,4567,72111,110N/A
12/31/2021103,42517,780N/AN/AN/A
9/30/2021100,41617,03310,47813,213N/A
6/30/202196,04416,311N/AN/AN/A
3/31/202188,65015,85011,05112,649N/A
12/31/202087,21815,338N/AN/AN/A
9/30/202085,97114,6488,91611,455N/A
6/30/202084,98413,636N/AN/AN/A
3/31/202083,44411,2712,2205,851N/A
12/31/201981,48411,057N/AN/AN/A
9/30/201978,9299,2625,1738,756N/A
6/30/201975,4788,098N/AN/AN/A
3/31/201973,5727,6052,5057,797N/A
12/31/201870,1576,602N/AN/AN/A
9/30/201868,3186,293N/AN/AN/A
6/30/201867,7886,955N/AN/AN/A
3/31/201863,9186,309N/A2,660N/A
12/31/201760,0447,009N/AN/AN/A
9/30/201757,2857,626N/AN/AN/A
6/30/201755,0197,248N/AN/AN/A
3/31/201756,8758,920N/A4,711N/A
12/31/201656,9337,732N/AN/AN/A
9/30/201654,9927,267N/AN/AN/A
6/30/201652,4197,108N/AN/AN/A
3/31/201649,2487,416N/A7,258N/A
12/31/201547,9758,189N/AN/AN/A
9/30/201544,5567,227N/A4,023N/A
6/30/201540,4595,781N/AN/AN/A
3/31/201537,4343,916N/A3,255N/A
3/31/201431,1914,353N/A2,900N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALKEM's forecast earnings growth (10.7% per year) is above the savings rate (6.7%).

Earnings vs Market: ALKEM's earnings (10.7% per year) are forecast to grow slower than the Indian market (18.2% per year).

High Growth Earnings: ALKEM's earnings are forecast to grow, but not significantly.

Revenue vs Market: ALKEM's revenue (9.5% per year) is forecast to grow slower than the Indian market (11.1% per year).

High Growth Revenue: ALKEM's revenue (9.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ALKEM's Return on Equity is forecast to be low in 3 years time (18.6%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 23:35
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alkem Laboratories Limited is covered by 36 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nitin BhasinAmbit Capital
Prashant NairAmbit Capital
Shrikant AkolkarAngel Broking Private Limited